GWM
HRTX icon

Geneos Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Geneos Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-704
Closed -$7K – 2814
2021
Q3 		$7K Buy
704
+4
+0.6% +$49 ﹤0.01% 2349
2021
Q2 		$10K Sell
700
-1,625
-70% -$25.9K ﹤0.01% 2196
2021
Q1 		$40K Hold
2,325
– – ﹤0.01% 1741
2020
Q4 		$13K Buy
+2,325
New +$40.4K ﹤0.01% 2112
2017
Q1 		– Sell
-679
Closed -$8K – 2098
2016
Q4 		$8K Sell
679
-25
-4% -$392 ﹤0.01% 1503
2016
Q3 		$12K Hold
704
– – ﹤0.01% 1306
2016
Q2 		$12K Hold
704
– – ﹤0.01% 1273
2016
Q1 		$14K Buy
+704
New +$13.9K ﹤0.01% 1192

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geneos Wealth Management's HRTX Position: Q4 2021 in Review

Geneos Wealth Management sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 704 shares — an estimated $7K sold.

Geneos Wealth Management first reported a position in HRTX in Q1 2016 and held it in 8 quarters. The position peaked at $40K in Q1 2021. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

  • Geneos Wealth Management reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 704 Heron Therapeutics shares in Q4 2021, an estimated $7K.
  • Geneos Wealth Management first reported a position in Heron Therapeutics in Q1 2016 and held it in 8 quarters.
  • Geneos Wealth Management's Heron Therapeutics position peaked at $40K in Q1 2021.
  • 200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on Geneos Wealth Management's 13F filing for Q4 2021, filed 9 Feb 2022.